Board approves merger of two wholly owned units into Emcure Pharmaceuticals

Nclt Scheme FiledStrategic Transactions View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹1835.00

prior close

₹1878.00

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.1%+0.8% vs market

Pharmaceuticals peers, median of 167sector-0.1%+2.1% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.2

15m

+0.2

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9+1.1+0.8-0.1+2.1

Next day

+1.7+1.5+0.2-0.1+1.8

+1.4+1.5-0.1-0.3+1.6

+0.1+0.3-0.2-1.0+1.0

-0.7+0.4-1.1-0.8+0.1

-3.6-0.8-2.8-2.2-1.4

-3.0-4.1+1.1-4.7+1.7

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure board approved amalgamation of two wholly owned subsidiaries — Zuventus Healthcare (networth 871 crore, FY26 turnover 1,041 crore) and Emcutix Biopharmaceuticals (networth negative 13 crore, turnover 29 crore) — into itself. No new shares issued and no consideration paid as both are wholly owned. Aim is entity rationalization and operational efficiency. Scheme requires NCLT and other approvals under Sections 230 to 232 of the Companies Act 2013.

Likely market impact

Internal group restructuring; no change in shareholding or EPS dilution, but awaits NCLT approval. Likely neutral to mildly positive on operational efficiency.